Taysha Gene Therapies

TSHANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.885 B

$6.56 +3.47%

Close of 7 Aug 2026

Revenue

$9.77M

#3174 by revenue

Earnings

-$109.0M

Loss-making

Shares outstanding

287,269,885

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#34Adma BiologicsADMA$2.22B
#35MesoblastMESO$2.06B
#36Taysha Gene TherapiesTSHA$1.89B
#37Recursion PharmaceuticalsRXRX$1.72B
#38ImmunocoreIMCR$1.64B

Where these numbers come from

Share counts and financials for Taysha Gene Therapies are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.